Association of circulating serum MIR-34a and MIR-122 with dyslipidemia among patients with non-alcoholic fatty liver disease

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Salvoza, Noel C ^a,b   Klinzing, David C ^a,c   Gopez Cervantes, Juliet ^a   Baclig, Michael O ^a  

^a ST LUKE S MEDICAL CENTER   (Philippines)

^b WEST VISAYAS STATE UNIVERSITY   (Philippines)

^c Molecular Diagnostics Laboratory   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; MICRORNA 122; MICRORNA 125B; MICRORNA 21; MICRORNA 34A; MICRORNA 375; MICRORNA 39; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIRN122 MICRORNA, HUMAN; MIRN34 MICRORNA, HUMAN;

AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CAENORHABDITIS ELEGANS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; FATTY LIVER; FEASIBILITY STUDY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; VALIDATION PROCESS; ADULT; ANIMAL; BLOOD; COMPLICATION; DYSLIPIDEMIAS; FEMALE; GENETICS; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; UPREGULATION; YOUNG ADULT;

ADULT; ANIMALS; CAENORHABDITIS ELEGANS; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; LIVER; MALE; MICRORNAS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; UP-REGULATION; YOUNG ADULT;

EID: 84964336921     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153497     Document Type: Article

References (38)

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, etal. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology and the American Gastroenterological Association. Am J Gastroenterol 2012 107:811-826. doi:10.1038/ajg.2012.128 PMID: 22641309
2. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L. Findings and recommendations from an American Association for the Study of Liver Diseases US Food and Drug Administration Joint Workshop. Hepatology 2015 61:1392-1405.
3. Spengler EK, Loomba R. Recommendations for diagnosis, referral for liver biopsy and treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Mayo Clin Proc 2015 90:1233-1246. doi:10.1016/j.mayocp. 2015.06.013 PMID: 26219858
4. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: A review of available epidemiological data. J Hepatol 2013 58:593-608. doi:10.1016/j.jhep. 2012.12.005 PMID: 23419824
5. Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol 2013 10:645-655. doi:10.1038/nrgastro.2013.182 PMID: 24061205
6. Agrawal S, Duseja AK. Non-alcoholic fatty liver disease: East versus West. J Clin Exp Hepatol 2012 2:122-134. doi:10.1016/S0973-6883 (12) 60101-7 PMID: 25755421
7. Angulo P. Nonalcoholic fatty liver disease. N EnglJ Med 2002 346:1221-1231. PMID: 11961152
8. Ferreira DM, Simão AL, Rodrigues CM, Castro RE. Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease. FEBS J 2014 281:2503-2524. doi:10.1111/febs.12806 PMID: 24702768
9. Petta S, Di Marco V, CammàC, Butera G, Cabibi D, Craxì A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: The effects of body mass index. Aliment Pharmacol Ther 2011 33:1350-1360. doi:10.1111/j.1365-2036.2011.04668.x PMID: 21517924
10. Piscaglia F, Marinelli S, Bota S, Serra C, Venerandi L, Leoni S, et al. The role of ultrasound elastographic techniques in chronic liver disease: Current status and future perspectives. Eur J Radiol 2014 83:450-455. doi:10.1016/j.ejrad.2013.06.009 PMID: 23891139
11. ™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010 36:1825-1835. doi:10.1016/j.ultrasmedbio.2010.07. 005 PMID: 20870345
12. Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, et al. Controlled attenuation parameter (CAP): A noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012 32:902-910. doi:10.1111/j.1478-3231.2012.02781.x PMID: 22435761
13. Shen F, Zheng RD, Mi YQ, Wang XY, Pan Q, Chen GY, etal. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol 2014 20:4702-4711. doi:10.3748/wjg.v20.i16.4702 PMID: 24782622
14. Hyysalo J, Männistö VT, Zhou Y, Arola J, KärjäV, Leivonen M, etal. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol 2014 60:839-846. doi:10.1016/j.jhep. 2013.12.009 PMID: 24333862
15. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001 294:862-864. PMID: 11679672
16. Ambros V. The functions of animal microRNAs. Nature 2004 431:350-355. PMID: 15372042
17. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013 10:542-552. doi:10.1038/nrgastro.2013.87 PMID: 23689081
18. Roderburg C, Luedde T. Circulating microRNAs as markers of liver inflammation, fibrosis and cancer. J Hepatol 2014 61:1434-1437. doi:10.1016/j.jhep. 2014.07.017 PMID: 25306489
19. Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, etal. Non-alcoholicsteatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008 48:1810-1820. doi:10.1002/hep. 22569 PMID: 19030170
20. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011 6(8):e23937. doi:10.1371/journal.pone.0023937 PMID: 21886843
21. Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H, et al. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int 2014 34:e302-7. doi:10.1111/liv. 12429 PMID: 24313922
22. Leti F, Malenica I, Doshi M, Courtright A, Van Keuren-Jensen K, Legendre C, etal. High-throughput sequencing reveals altered expression of hepatic microRNAs in non-alcoholic fatty liver diseaserelated fibrosis. Transl Res 2015 166:304-314. doi:10.1016/j.trsl.2015.04.014 PMID: 26001595
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta Ct) Method. Methods 2001 25:402-408. PMID: 11846609
24. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, etal. Real-time quantification of micro-RNAs by stem-loop RT-PCR. Nucleic Acids Res 2005 33:e179. PMID: 16314309
25. Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, etal. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch 2011 458:511-23. doi:10.1007/s00428-011-1066-1 PMID: 21442288
26. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology 2003 37:1202-1219. PMID: 12717402
27. World Health Organization. A healthy lifestyle. http://www.euro.who.int/en/health-topics/diseaseprevention/nutrition/a-healthy-lifestyle. Accessed 23 November 2015.
28. Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 2011 6:e28486. doi:10.1371/journal.pone.0028486 PMID: 22174818
29. Köberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, etal. Serum micro-RNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 2013 49:3442-3449. doi:10.1016/j.ejca.2013.06.002 PMID: 23810247
30. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, etal. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci 2008 105:10513-10518. doi:10.1073/pnas.0804549105 PMID: 18663219
31. Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, etal. Associations between circulating microRNAs (miR-21, miR-34a, miR-122and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 2013 424:99-103. doi:10.1016/j.cca.2013.05.021 PMID: 23727030
32. Meyer SU, Pfaffl MW, Ulbrich SE. Normalization strategies for microRNA profiling experiments: A normal way to a hidden layer of complexity? Biotechnol Lett 2010 32:1777-1788. doi:10.1007/s10529-010-0380-z PMID: 20703800
33. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative Ct method. Nat Protoc 2008 3:1101-1108. PMID: 18546601
34. Farina NH, Wood ME, Perrapato SD, Francklyn CS, Stein GS, Stein JL, etal. Standardizing analysis of circulating microRNA: Clinical and biological relevance. J Cell Biochem 2014 115:805-811. doi:10. 1002/jcb.24745 PMID: 24357537
35. Yamada H, Ohashi K, Suzuki K, Munetsuna E, Ando Y, Yamazaki M, et al. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease. Clin Chim Acta 2015 446:267-271. doi:10.1016/j.cca.2015.05.002 PMID: 25958847
36. Zelber-Sagi S, Salomone F, Yeshua H, Lotan R, Webb M, Halpern Z, et al. Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease. Liver Int 2014 34:e128-135. doi:10.1111/liv. 12318 PMID: 24118857
37. Rottiers V, Näär AM. MicroRNAsin metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012 13:239-250. doi:10.1038/nrm3313 PMID: 22436747
38. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, etal. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 2009 10:R64. doi:10. 1186/gb-2009-10-6-r64 PMID: 19531210